Bio-techne Corp · NASDAQ:TECH
Bio-techne — Investor Presentation (January 2024)
26 slides from Bio-techne's investor presentation, January 2024
Slide 1: Purposeful Innovation Leads to Better Answers
Purposeful Innovation Leads to Better Answers Corporate Presentation - January 2024 Kim Kelderman Chief Operating Officer & Incoming Chief Executive Officer © 2024 Bio-Techne®. All rights reserved. | 1
Slide 2: Safe Harbor Cautionary Statements
Safe Harbor C A U T I O N A R Y S TAT E M E N T S This presentation contains “forward-looking “expects,” “expect,” “forecast,” “would,” “estimate,” We undertake no obligation to update any statements” within the meaning of the federal “will,” or similar references to future forward-looking statement
Slide 3: Kim Kelderman
Kim Kelderman PURPOSEFUL INNOVATION LEADS TO BETTER ANSWERS CEO AS OF FEBRUARY 1, 2024 Global executive Successfully served as President with experience running small, of Bio-Techne’s Diagnostics and medium and large businesses of Genomics Segment since 2018 various complexity • Doubled revenue of S
Slide 4: Mission
MISSION We focus on improving the quality of life by catalyzing advances in science and medicine. PURPOSEFUL INNOVATION LEADS TO BETTER ANSWERS © 2024 Bio-Techne®. All rights reserved. | 4
Slide 5: A Sustainable Future
A Sustainable Future Published our third Corporate Sustianability Report Environmental Social Governance Continued progress toward Diverse and inclusive workplace: Board includes: sustainability at largest manufacturing site: • ISO 14001 Certification • 49% of global workforce are female • Deep scie
Slide 6: Business Overview
PURPOSEFUL INNOVATION LEADS TO BETTER ANSWERS Business Overview © 2024 Bio-Techne®. All rights reserved. | 6
Slide 7: Portfolio of Proven Products $1.1B
CONSUMABLES-FOCUSED Portfolio of Proven Products President & CEO Chuck Kummeth Product Portfolio Instruments Services Incoming CEO 10% 7% Royalties Protein Sciences Kim Kelderman 2% Proteins Antibodies Headquarters Minneapolis, MN Proteomic Immunoassays Analytical Number of Employees FY2023 Revenues
Slide 8: FY23 Revenue Breakdown ($1.1B)
FY23 Revenue Breakdown ($1.1B) Segments & Product End Markets Markets Geographies 74% Protein Sciences 26% Diagnostics & Segment Genomics Segment Spatial Biology 13% 9% Liquid Biopsy & MDx Distributors EMEA 24% 5% 12% 50% 17% Core 44% Core Diagnostics 60% Pharma/ Americas Biotech China 10% 23% 20% 7
Slide 9: Large Addressable End Markets: ~$27B
Large Addressable End Markets: ~$27B Market Historic 5-Yr Bio-Techne End Markets Market Size Growth Rate Bio-Techne CAGR Market Penetration Core Products* ~$6B Mid-Single Digit 7% ~10% Proteomic Analytical ~$3B Low-Double Digit 19% ~10% Instruments Spatial Biology ~$5B Low-Double Digit 15% >2% Liqui
Slide 10: Strategic Pillars
Strategic Pillars Grow & Capitalize on Market Expansion Best-in-Class Leverage High Potential Through Innovation & Customer the Core Markets Acquisition Experience Develop People Through a Transformative Culture © 2024 Bio-Techne®. All rights reserved. | 10
Slide 11: Our Expansion Into Growth Verticals
PURPOSEFUL INNOVATION LEADS TO BETTER ANSWERS Our Expansion Into Growth Verticals © 2024 Bio-Techne®. All rights reserved. | 11
Slide 12: Core Products Enable Growth Verticals
Core Products Enable Growth Verticals DELIVERING COMPREHENSIVE WORKFLOW SOLUTIONS Proteomic Analytics Core Products Spatial Biology Antibodies Proteins Immunoassay Liquid Biopsy & Molecular Dx Calibrators & Controls Small Molecules Cell Culture & Gene Therapy © 2024 Bio-Techne®. All rights reserved.
Slide 13: Core Products
Core Products Addressable Market: ~$6B Proteins Antibodies Small Molecules Immunoassays Diagnostic Controls & Calibrators Market Growth: Mid-Single Digit Bio-Techne Market Share: ~10% Bio-Techne 5 Year Trailing CAGR: ~7% Leading Largest Wide range Broad menu of Most cited portfolio commercial of inn
Slide 14: What Makes Our Protein & Antibody Content Special?
What Makes Our Protein & Antibody Content Special? BEST IN CLASS CONTENT IS OUR ENGINE Choice Confidence Continued Innovation • Over 6,000 RUO & GMP Proteins • Stringent quality standards • Scaling of factories & yields and dedicated GMP facilities • Over 400,000 antibodies • Pairing AI (alpha fold)
Slide 15: Proteomic Analytical Instruments
Proteomic Analytical Total Addressable Market: >$3B Instruments Market Growth: Low-Double Digit Simple Western Biologics Bio-Techne Market Share: Only fully automated Bioprocessing instrument western blot solution for for protein purity, charge ~10% protein identification and and identity analysis a
Slide 16: Expanding Proteomic Analytical Instrument Applications & Markets
Expanding Proteomic Analytical Instrument Applications & Markets Biologics Simple Western Simple Plex Legacy Application Legacy Application Legacy Application • Protein purity, charge and identity • Fully automated western blot solution • Automated multiplexing ELISA solution for research use Expand
Slide 17: Spatial Biology
Spatial Biology Total Addressable Market: Fully Automated Spatial ~$5B Multiomic Workflow Market Growth: Low-Double Digit Bio-Techne Market Share: >2% Bio-Techne 5 Year Trailing Tissue Pre- Reagent Loading Probe Automated RNA Automated Processing Slide Loading Hybridization + Detection Protein Detec
Slide 18: Our Vision for Powering Multiomic Spatial Biology
Our Vision for Powering Multiomic Spatial Biology Diseases Involving the Immune System (Cancer/IO, Inflammation, Auto-Immunity) Pathology Immune Cell Cell Function Disease Identification Cytokine Cell and Gene Markers Chemokine Pathology Protein biomarkers Therapies with clinical utility CAR T, TCR
Slide 19: Liquid Biopsy & Molecular Diagnostics
Liquid Biopsy & Molecular Diagnostics Total Addressable Market: Screening Diagnosis Monitoring ~$9B Many patients Frequent tests Market Growth: Fragile X CFTR Fragile X C9orf72 BCR-ABL (CML) Low-Double Digit Current SMA TRIO SMA HTT Products CFTR DMPK Bio-Techne Market Share:
Slide 20: Bringing Exosomes to the Forefront of Liquid Biopsy
Bringing Exosomes to the Many liquid biopsy (LBx) products use cell-free DNA (cfDNA) or circulating tumor cells (CTCs). Exosomes Forefront of Liquid Biopsy are a more abundant and a richer source of biological information BRAF Key Properties CTC cfDNA Exosomes copies/mL 64000 Analyte RNA+DNA DNA onl
Slide 21: Cell & Gene Therapy
Cell & Gene Therapy Total Addressable Market: ~$4B Cell Culture Regenerative Medicine Immune Cell Therapy Market Growth: >20% Bio-Techne Market Share: G-Rex UltiMatrix, BMEs ~2% Bio-Techne 5 Year Trailing CAGR: RUO Media & Supplements ~50% RUO Small GMP Media GMP Proteins Molecules Brands GMP Small
Slide 22: Aseptic Immune Cell Therapy Manufacturing Solution
Aseptic Immune Cell Therapy Manufacturing Solution Clinically TcBuster Proven GMP Non-viral Media Gene Engineering GMP Closed Process Cytokine G-Rex Sized GMP Delivery * Cytokines *Bio-Techne currently owns 20% equity investment in Wilson Wolf with an agreement to acquire the remainder of the compan
Slide 23: Translating an M&A Strategy Into Financial Results
PURPOSEFUL INNOVATION LEADS TO BETTER ANSWERS Translating an M&A Strategy Into Financial Results © 2024 Bio-Techne®. All rights reserved. | 23
Slide 24: Successful Acquisition Strategy Has Led to Sustained & Accelerated Growth
Successful Acquisition Strategy Has Led to Sustained & Accelerated Growth Pre-FY13 FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 1,200 REVENUE ($ MILLION) 1,000 800 600 400 200 0 Pre-FY13 FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 ACQ U I S I T I O N S T R AT E G Y H A S C R E AT E D A N
Slide 25: Business Positioned for Long-Term Growth
Business Positioned for Long-Term Growth Proteomic Spatial Liquid Biopsy & Cell Culture & Analytics Biology Molecular Dx Gene Therapy Core Products Antibodies Proteins Immunoassay Continued market and Leverage ACD and Continued ExoDx Prostate test Provide cost Calibrators & Controls applications exp
Slide 26: © 2024 Bio-Techne ® . All rights reserved. | 26
© 2024 Bio-Techne®. All rights reserved. | 26